Live Science on MSN
New tests could nearly halve the rate of late-stage cancers, some scientists say — is that true?
The study suggests the tests could save lives by catching cancer at earlier stages, when it's more easily treated. It predicted that, over a decade of use, MCEDs could reduce stage IV cancer diagnoses ...
The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...
TrinScreen HIV order signals renewed strength in global HIV testing market- Company also reports a key milestone of Adjusted EBITDA1positive ...
ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...
A proof of concept study suggests an FT-IR microspectroscopy blood test can detect a single circulating tumour cell in a lung cancer patient, supporting future real time monitoring.
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...
Scientists at Northern Arizona University are developing a promising new way to detect Alzheimer’s disease earlier than ever before—by tracking how the brain uses sugar. Using tiny particles in the ...
Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.
The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
PALO ALTO, Calif. & ROME--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results